Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

BACKGROUND: The combination of PD-1/PD-L1 inhibitor and chemotherapy has been clinically confirmed to be beneficial as the first-line treatment of patients with advanced NSCLC. This study aimed to assess the effect of nivolumab + docetaxel versus nivolumab monotherapy in patients with NSCLC after th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yang, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Wu, Di, Long, Jieran, Zhang, Ziran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783906/
https://www.ncbi.nlm.nih.gov/pubmed/34131807
http://dx.doi.org/10.1007/s00262-021-02964-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783906/
https://www.ncbi.nlm.nih.gov/pubmed/34131807
http://dx.doi.org/10.1007/s00262-021-02964-x

Ejemplares similares